Biohaven reports >90% IgG reduction with BHV-1300 bispecific degrader after repeat dosing

Biohaven Ltd.

BHV-1300 bispecific IgG degrader achieved >90% reduction in IgG after repeat dosing in pharmacodynamic study.
The data was disclosed in a new corporate presentation dated September 27, 2023.
BHV-1300 targets elimination of pathogenic IgG for autoimmune disease therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.